DEREK E BYERS

Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease SAINT LOUIS, MO NPI 1407074701

General Payments — all program years on this page

$835,201.58

  • Category: General Payments
  • Program years: PY2018–2023
  • Record count: 30
  • As of (CMS publication): 2026-01-23

Latest program year (PY2023): $218,000.00 across 14 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2023) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $218,000.0014

By paying entity

Latest program year (PY2023) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $218,000.0014

By program year

Program yearAmountRecords
2018 $345.001
2019 $56.583
2021 $308,800.006
2022 $308,000.006
2023 $218,000.0014

Records — PY2023 (14)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1011781587 AstraZeneca Pharmaceuticals LP $8,800.00 02/17/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1011826373 AstraZeneca Pharmaceuticals LP $9,800.00 02/17/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1011906159 AstraZeneca Pharmaceuticals LP $200.00 02/17/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1012020119 AstraZeneca Pharmaceuticals LP $49,400.00 04/05/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1012113885 AstraZeneca Pharmaceuticals LP $7,400.00 07/05/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1014202347 AstraZeneca Pharmaceuticals LP $5,600.00 02/17/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1015322527 AstraZeneca Pharmaceuticals LP $1,200.00 02/17/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1015365163 AstraZeneca Pharmaceuticals LP $400.00 02/17/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1015416639 AstraZeneca Pharmaceuticals LP $200.00 02/17/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1015649145 AstraZeneca Pharmaceuticals LP $43,600.00 04/05/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1015686149 AstraZeneca Pharmaceuticals LP $1,000.00 02/17/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1016003221 AstraZeneca Pharmaceuticals LP $57,400.00 04/05/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1016081777 AstraZeneca Pharmaceuticals LP $16,200.00 02/08/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1016102091 AstraZeneca Pharmaceuticals LP $16,800.00 04/05/2023 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.